Protocol 20130287

This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate safety, tolerability, and efficacy of evolocumab (AMG 145) on LDL-C in subjects with Type 2 Diabetes Mellitus and hypercholesterolemia/mixed dyslipidemia on maximally tolerated statin therapy.

The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in subjects with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.


Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434